Search

Displaying results 3181 - 3190 of 10000 in total
  1. Pathway

    Cardiolipin Biosynthesis CL(15:0/15:0/15:0/15:0)

    smpdb.ca/view/SMP0204337
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  2. Drug

    Hydroxyethyl cellulose

    go.drugbank.com/drugs/DB11602
    Approved

    Hydroxyethyl cellulose is a polysaccharide derivative with gel thickening, emulsifying, bubble-forming, water-retaining and stabilizing properties. … It is used as a key ingredient in many household cleaning products, lubricants and cosmetics due to its non-ionic and water-soluble nature.

    Salts: Hydroxyethyl cellulose (1500 MPa.s at 1%), Hydroxyethyl cellulose (100 MPa.s at 2%)Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Merimepodib

    go.drugbank.com/drugs/DB04862
    Investigational

    Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. … Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.

  4. Drug

    Dihydroergocristine

    go.drugbank.com/drugs/DB13345
    Approved

    [L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.

    Mixtures: TOTERJİN DAMLA, 50 CCCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Pathway

    Cardiolipin Biosynthesis CL(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))

    smpdb.ca/view/SMP0255944
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  6. Drug

    Pancrelipase amylase

    go.drugbank.com/drugs/DB11065
    ApprovedInvestigational

    [T177] The pancrelipase amylase is a single polypeptide chain containing two SH groups and four disulfide bridges. … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.

    Mixtures: Pancrease Mt 10, Creon 10 MinimicrospheresSynonyms: Amylase A
  7. Pathway

    Cardiolipin Biosynthesis CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))

    smpdb.ca/view/SMP0245116
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  8. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    Phase 2a studies are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 participating countries[L31703], and for participants with PSC (NCT04480840). … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical

  9. Drug

    MM-111

    go.drugbank.com/drugs/DB17983
    Investigational

    MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.

  10. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]